Treatment of Functional Dyspepsia (Indigestion) with Unani medicine Majoone-Sangdana Murgh

Phase 3

Not yet recruiting

• Conditions: Functional dyspepsia,

• Registration Number: CTRI/2019/02/017801
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM

Brief Summary

This study is designed as a multicentric open trial in patients with  **Du‘f al-Mi‘da (Functional Dyspepsia).**After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria.  The patients will be assessed clinically at every two weeks. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be six weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

**Compositionof** ***Majoon-e-Sangdana Murgh***

| | | | |

| --- | --- | --- | --- |

|**S. No.**

**Ingredients**

**Botanical / Scientific Name**

**Quantity**

|1.

Gul-e-Surkh

*Rosa damascena* Mill.

100 g

|2.

Post-e-Sangdana Murgh

Gizzard of the Cock/ Hen

90 g

|3.

Tabasheer

*Bambusa arundinacea*

90 g

|4.

Behman Safaid

*Centaurea behen* Linn.

70 g

|5.

Behman Surkh

*Salvia haematodes* Linn.

70 g

|6.

Sandal Surkh

*Pterocarpus santalinus* Linn*.*

70 g

|7.

Sandal Safaid

*Santalum album* Linn*.*

70 g

|8.

Saatar Farsi

*Zataria multiflora* Boiss*.*

70g

|9.

Kishneez Khushk Biryan

*Coriandrum sativum* Linn*.*

70 g

|10.

Habb-ul-Aas

*Myrtus communis* Linn*.*

70 g

|11.

Pudina Khushk

*Mentha arvensis* Linn*.*

45 g

|12.

Post-e-Berun-e-Pista

*Pistacia vera* Linn*.*

45 g

|13.

Post-e-Turanj

*Citrus medica* Linn*.*

45 g

|14.

Post-e-Halela Zard

*Terminalia chebula* Retz*.*

45 g

|15.

Qand Safaid

Sugar

3 kg

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2019-02-21
• Study Start: 2019-02-28

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

· Patients of either sex in the age group of 18-60 · Patients meeting the Rome III diagnostic criteria for PDS.

Exclusion Criteria

• · Presence of GI ulcer, erosive gastritis, atrophic gastritis, severe dysplasia of gastric mucosa or suspicious malignant lesion.
• · Having overlap syndrome combined with gastro esophageal reflux disease or irritable bowel syndrome · Having alarm symptoms (weight loss, black or tar stool, dysphasia, etc.) · Having any systemic disease (diseases of heart, lung, liver or kidney) or mental illness · History of surgery related with the gastrointestinal tract more than six months ago · Taking drugs which may affect the gastro intestinal tract, such as non-steroidal antiinflammatory drugs and aspirin · Known Allergy to the experimental medications · Pregnant and breastfeeding · Refusing to sign the informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of Du‘f al-Mi‘da (Functional Dyspepsia)	6 weeks

Secondary Outcome Measures

Name	Time	Method
Investigations will be done at baseline and end of treatment	6 weeks

Trial Locations

Locations (3)

Central Research Institute of Unani Medicine (CRIUM); 🇮🇳 Hyderabad, TELANGANA, India

Regional Research Institute of Unani Medicine; 🇮🇳 Aligarh, UTTAR PRADESH, India

Regional Research Institute of Unani Medicine (RRIUM); 🇮🇳 Bhadrak, ORISSA, India

Central Research Institute of Unani Medicine (CRIUM)

🇮🇳Hyderabad, TELANGANA, India

Dr Ahmed Minhajuddin

Principal investigator

9177376011

ahmedminhajuddin@yahoo.com